Covidien Loses Bid To Block Generic Restoril

Law360, New York (August 5, 2009, 5:15 PM EDT) -- Covidien Ltd. has been thwarted in its attempt to block URL Pharma Inc. from launching a generic version of the sleep disorder drug Restoril when a U.S. Food and Drug Administration stay expires later in August.

Judge Stanley Chesler of the U.S. District Court for the District of New Jersey on Tuesday denied Covidien's motion to enjoin URL Pharma from marketing or selling a generic 7.5 mg temazepam product, ruling that the generic would not literally infringe a claim of Covidien's patent.

The patent-at-issue is U.S....
To view the full article, register now.